Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRG Bullfrog AI	$1.27 +5.8%	$1.46	$1.17 ▼ $4.84	$12.10M	0.47	115,967 shs	186,893 shs
CSCI COSCIENS Biopharma	$3.29 +21.9%	$3.56	$1.96 ▼ $6.18	$8.50M	0.91	5,211 shs	91,783 shs
TXMD TherapeuticsMD	$1.10 +1.8%	$1.14	$0.70 ▼ $2.44	$12.50M	0.42	21,600 shs	21,585 shs
UBX UNITY Biotechnology	$0.18 -40.4%	$0.43	$0.20 ▼ $3.10	$3.08M	0.92	284,137 shs	3.73 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRG Bullfrog AI	+5.83%	+1.60%	-18.06%	-31.35%	-52.96%
CSCI COSCIENS Biopharma	+24.91%	+11.90%	-20.72%	-7.32%	+328,999,900.00%
TXMD TherapeuticsMD	+1.84%	-5.98%	-8.34%	-24.14%	-34.72%
UBX UNITY Biotechnology	0.00%	0.00%	0.00%	-77.02%	-88.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRG Bullfrog AI	0.4241 of 5 stars	0.0	3.0	0.0	0.0	0.6	2.5	0.0
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	0.1482 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.0	0.6
UBX UNITY Biotechnology	2.3439 of 5 stars	3.2	0.0	0.0	4.7	0.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A
UBX UNITY Biotechnology	2.33	Hold	$2.33	1,203.54% Upside

Current Analyst Ratings Breakdown

Latest UBX, TXMD, BFRG, and CSCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/27/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRG Bullfrog AI	$60K	213.36	N/A	N/A	$0.22 per share	5.77
CSCI COSCIENS Biopharma	$9.59M	1.08	N/A	N/A	$2.26 per share	1.46
TXMD TherapeuticsMD	$1.76M	7.23	N/A	N/A	$2.36 per share	0.47
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	$0.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRG Bullfrog AI	-$6.99M	-$0.76	N/A	∞	N/A	N/A	-195.35%	-162.37%	N/A
CSCI COSCIENS Biopharma	-$15.31M	-$6.01	N/A	∞	N/A	-199.55%	-149.49%	-54.80%	11/11/2025 (Estimated)
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	11/10/2025 (Estimated)
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	N/A

Latest UBX, TXMD, BFRG, and CSCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CSCI COSCIENS Biopharma	N/A	-$0.85	N/A	-$0.85	N/A	$2.75 million
8/13/2025	Q2 2025	BFRG Bullfrog AI	N/A	-$0.15	N/A	-$0.15	N/A	$0.03 million
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRG Bullfrog AI	N/A	3.97	3.97
CSCI COSCIENS Biopharma	N/A	2.98	2.54
TXMD TherapeuticsMD	N/A	2.89	2.89
UBX UNITY Biotechnology	N/A	1.95	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRG Bullfrog AI	0.96%
CSCI COSCIENS Biopharma	0.73%
TXMD TherapeuticsMD	30.74%
UBX UNITY Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
BFRG Bullfrog AI	24.72%
CSCI COSCIENS Biopharma	0.10%
TXMD TherapeuticsMD	2.30%
UBX UNITY Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRG Bullfrog AI	4	10.08 million	7.59 million	Not Optionable
CSCI COSCIENS Biopharma	20	3.15 million	3.14 million	N/A
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable

UBX, TXMD, BFRG, and CSCI Headlines

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice

June 30, 2025 | finance.yahoo.com

Unity Biotechnology stock plunges after Nasdaq delisting notice

June 30, 2025 | za.investing.com

Unity Biotechnology Inc News (UBX) - Investing.com

June 26, 2025 | investing.com

UBX Unity Biotechnology, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 6, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.comF

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.comO

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.comT

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UBX, TXMD, BFRG, and CSCI Company Descriptions

Bullfrog AI NASDAQ:BFRG

$1.27 +0.07 (+5.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.26 -0.01 (-0.79%)

As of 08/22/2025 06:55 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

COSCIENS Biopharma NASDAQ:CSCI

$3.29 +0.59 (+21.85%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.29 0.00 (0.00%)

As of 08/22/2025 07:39 PM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

TherapeuticsMD NASDAQ:TXMD

$1.10 +0.02 (+1.84%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$1.08 -0.02 (-1.81%)

As of 08/22/2025 07:40 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

UNITY Biotechnology NASDAQ:UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time